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Autosomal dominant Alzheimer s disease (ADAD) individuals present amyloid deposits 
before symptoms onset. We aimed to investigate efficacy and safety of 18F- florbetaben 
(FBB) for assessing amyloid deposition in ADAD.  We acquired FBB-PET and MRI of 25 
individuals from PSEN1 families (NCT02362880). We studied individual uptake patterns, 
group differences, and correlation with estimated years to symptoms onset (EYO), as well as 
adverse events (AE). We found that asymptomatic carriers (N=14) showed increased FBB 
uptake across the cerebral cortex and in the caudate. FBB accumulation appeared more than 
15 years before onset in precuneus and bankssts, among other regions, overlapping regions 
showing increased cortical thickness in the same subjects. FBB uptake correlated with EYO 
in several areas, especially the rostral anterior cingulate. Symptomatic carriers (N=7) had an 
elevated FBB uptake plateau. No AE were reported. Overall, we found progressive FBB 
uptake in ADAD starting two decades before symptoms. The rostral anterior cingulate is a 





















Autosomal dominant Alzheimer s disease (ADAD), with almost 100% penetrance, allows the 
study of the trajectories of different biomarkers and the evaluation of disease-modifying 
treatments at early or presymptomatic stages of the disease (Bateman et al., 2011). In 
addition, the relatively predictable age of onset in ADAD allows the calculation of the 
estimated years to symptom onset (EYO), as a proxy of the distance to symptoms onset for 
each asymptomatic mutation carrier. This facilitates the comparison between individuals with 
different mutations and the study of the progression of the disease even in cross-sectional 
samples. Using the EYO measure, research on ADAD, has revealed a temporal ordering of 
biomarkers indicating that the first pathological changes appear during the asymptomatic 
stage in target core regions and that these progressively expand towards new regions of the 
brain as the disease symptoms worsen. Brain amyloid-  (A ) accumulation is one of these 
biomarkers, and two ongoing trials, the Dominantly Inherited Alzheimer Network Trials Unit 
(Mills et al., 2013) and the Alzheimer’s Prevention Initiative (Carrillo et al., 2013), are 
already testing drugs that aim to limit the amyloid accumulation in the brain in both ADAD 
and sporadic Alzheimer s disease (AD).  
Positron emission tomography (PET) imaging is a reliable tool to explore the patterns of 
amyloid deposition.  Different amyloid-PET tracers available have demonstrated accurate 
correlation with post-mortem amyloid deposition. In ADAD, both the 11C-Pittsburgh 
compound B (PIB) (Bateman et al., 2012; Benzinger et al., 2013; Gordon et al., 2018; Quiroz 
et al., 2018; Rodriguez-Vieitez et al., 2016) and the 18F-Florbetapir (Fleisher et al., 2012) 
tracers have been used, detecting elevated amyloid uptake about 15 years before estimated 
symptom onset. In addition, some of the ADAD patients show relevant and early striatal 
amyloid tracer binding that is not frequent in sporadic AD (Benzinger et al., 2013).   
However, it has not yet been established whether different amyloid tracers bind to identical 
sites on A  fibrils, offering the same ability to detect the regional A  burden. Regional and 
temporal disparities in fibrillar A  accumulation might have important implications for 
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clinical trials. On the other hand, even if PIB-PET is considered the gold standard for amyloid 
tracers, its availability is more limited worldwide, given that it is a Carbon-tracer.  
Florbetaben (FBB: trans-4-(N-methyl-amino)-4-{2-[2-(2-[18F]fluoroethoxy) ethoxy]-ethoxy} 
stilbene; Neuraceq ) has high affinity and specificity for A , lack of binding to Lewy bodies 
or neurofibrillary tangles in post-mortem tissue at low nanomolar concentrations, and 
excellent correlation with global PiB retention (Rowe et al., 2017). However, no studies have 
been published to date examining the spatial pattern and chronology of FBB binding in 
ADAD mutation carriers.  In this study, we investigate for the first time the efficacy and 
safety of the -amyloid tracer 18F-Florbetaben (FBB) for assessing the regional and 
chronological amyloid deposition pattern in ADAD due to PSEN1 mutations.  
2. MATERIAL AND METHODS 
 
2.1. Participants  
Participants were recruited within the genetic counselling programme for familial dementias 
(PICOGEN) at the Hospital Clinic, Barcelona, Spain (Fortea et al., 2011). Participants were 
adult children (> 18 y) of symptomatic ADAD patients with a mutation in the PSEN1 gene 
and who were either cognitively normal (Clinical Dementia Rating CDR=0) or had mild 
symptoms of cognitive decline (CDR 0.5 or 1). Exclusion Criteria were the presence of any 
condition precluding the completion of the study, any major medical disease, especially 
severe liver disease (AST /ALT > 5 x ULN) or advanced renal insufficiency (creatinine > 2 x 
ULN), current or previous history of alcohol abuse or epilepsy, known allergy to florbetaben 
or its constituents, pregnancy or breast feeding or planned pregnancy during the study period, 
and any medical or psychiatric disease other than ADAD, which could cause disturbance of 
brain function or cognition.  
The study was approved by the Hospital Clinic ethics committee and all subjects gave written 
informed consent. According to the Spanish regulations related to the use of radiotracers in 
human subjects, the study was registered as a clinical trial (EudraCT No. 2014-000763-41, 
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protocol code FBB-FAD-2014, ClinicalTrials.gov Identifier: NCT02362880) and approved 
by the Spanish Drugs and Medical Products Agency (AEMPS).   
Participants were classified as asymptomatic if they had no cognitive complaints, their 
cognitive performance was normal, and they scored 0 on the CDR scale, or as symptomatic if 
their CDR score was >0 or if their cognitive performance was  1.5 SD below the mean. In 
addition, according to their genetic status, participants were classified as mutation carriers 
(MC), either asymptomatic or symptomatic MC (AMC or SMC), and non-carriers or controls 
(CTR).   
We calculated the EYO for AMC as the subject s age at the time of the study minus their 
parental age at symptoms onset. Further, we divided the AMC into two groups: stage I-AMC, 
those younger than 15 years from estimated symptoms onset, and stage II AMC, older than 
15 years from estimated symptoms onset. In SMC we calculated EYO as the subject s age at 
the time of the study minus their real age at symptoms onset. 
 
2.2. Safety measures 
Safety measures were recorded at the moment of the PET acquisition and after 24 hours. We 
recorded adverse events (AE) spontaneously reported by the participant, discovered as a 
result of general questioning by the study staff, or determined by physical examination, as 
well as findings of the medical and neurological examination and vital signs (blood pressure, 
heart rate, temperature).  
  
2.3. MRI acquisition 
Participants were examined on a 3T MRI scanner (Magnetom Trio Tim, Siemens Medical 
Systems, Germany). A high-resolution 3D structural data set (T1-weighted, MP-RAGE, TR = 
2300 ms, TE = 2.98 ms, voxel size = 1x1x1 mm; FoV= 256 mm) was acquired. Two subjects 





2.4. PET acquisition  
Each participant received a single intravenous bolus of approximately 300 MBq (8.1 mCi) of 
[18F] Florbetaben, followed by a saline flush. Eighty minutes post-injection participants were 
scanned in a Siemens Biograph molecular-CT. The scanning included a low dose CT (50 
mAs, 120 kV) for attenuation correction and a PET acquisition consisting in 4 5-minute 
dynamic 3D frames. PET images were corrected for attenuation, deathtime, dispersion and 
decay and reconstructed using an iterative algorithm (TRUEX+TOF; 8 iterations, 21 subsets, 
with a Gaussian post-filter FWWH of 3 mm), resulting in the final sequence of whole brain 
images of 109 planes (1.02 x 1.02 x 2.0 mm). Summed images were subsequently created for 
quantification and analyses. 
 
2.5. Visual analysis of PET images 
The visual pattern of tracer retention was evaluated by 2 physicians (authors N.F.  and F.L) 
blinded to the genetic and clinical status of the participants in the following areas: lateral 
temporal, frontal, parietal, posterior cingulate, precuneus, occipital, striatum and cerebellum. 
Interpretation of the images was made comparing activity of grey matter with activity in 
adjacent white matter. FBB uptake in each of these regions was classified as 
pathologic/positive or non-pathologic/normal. Furthermore, cortical retention was classified 
as focal retention if it was localized in a region or generalized uniform uptake if it covered 
several regions of the cortical mantle. 
 
2.6. MRI analysis 
Images were processed with Freesurfer (http://surfer.nmr.mgh.harvard.edu/), version 6.0. The 
Freesurfer stream includes cortical reconstruction and registration, subcortical segmentation 
(Fischl et al., 2002), delineation of pial and white matter surfaces, estimation of the cortical 
thickness (CTh), and parcellation of the cortical surface (Fischl et al., 2004).   
For whole-head segmentation of MRI data, we used an atlas specifically defined for PET 
analysis, consisting on 101 ROIs covering cortical and subcortical areas (Greve et al., 2016). 
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We performed visual validation of the surface reconstruction and the segmentation results. 
We calculated the mean CTh value within each cortical ROI of the atlas.  
 
2.7. Automated PET quantification and analysis 
Each individual PET scan was first registered to its corresponding MRI image using 
normalized mutual information (Greve and Fischl, 2009). All registrations were visually 
inspected.  
We obtained the standardized uptake value ratio (SUVR) for each of the atlas ROIs, 
calculated as the mean uptake in the ROI divided by the uptake in the region of reference. We 
used the pons as a reference region according to previous studies (Su et al., 2016).  
PET values were corrected for partial volume effects (PVE) using the geometrical transfer 
matrix (GTM) method (Greve et al., 2016). In order to reduce the number of measures, we 
calculated the bilateral mean (average between left and right) of the uptake in the main 
regions, resulting in 40 summary values per subject (6 subcortical and 34 cortical regions).  
We used a previously reported cutoff of 0.78 (Bullich et al., 2017) to calculate the number of 
subjects with high FBB uptake at each region within each group. However this threshold was 
obtained with results from a slightly different methodology based ROIs from the AAL atlas 
(Tzourio-Mazoyer, 2002). We used this threshold, as one of the most restrictive threshold 
reported in the mentioned study, in order to account for changes in the methodology 
(Freesurfer-based analysis with PVC versus AAL-based analysis with no PVC). In addition, 
to further explore these differences between methods, we obtained the quantification results 
with the AAL-based analysis. These methods, as well as the comparison between results from 
the two approaches are reported in Supplementary Material. 
 
2.8. Statistical analyses 
We compared the SUVR values between groups, using nonparametric tests in MATLAB. 
Specifically, we used Kruskal-Wallis and Mann-Whitney U for testing differences between 
groups of subjects. For each region we tested 4 hypotheses: (a) higher uptake in SMC 
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compared with CTR; (b) higher uptake in AMC compared with CTR; (c) higher uptake in 
stage I-AMC compared with CTR; and (d) higher uptake in stage I-AMC compared with 
CTR. We also used Spearman correlations to assess the association between individual SUVR 
scores and EYO, calculated in all MC and in AMC and SMC subjects separately.  
As regards CTh, we also performed group comparisons and correlation with EYO in the 34 
cortical bilateral parcellations. All tests were considered significant at p<0.05 level. We 
calculated differences after correction for multiple comparisons using the false discovery rate 
(FDR) correction, for each hypothesis and across all the regions evaluated, implemented in 
MATLAB (Benjamini & Hochberg, 1995), with a false discovery rate of q<0.05. 
3. RESULTS 
3.1. Sample characteristics 
Twenty-five participants from ADAD families caused by 12 different PSEN1 mutations 
(E120K, H131R, V151M, H163R, S169P, L173F, G209E, K239N, L282R, L286P, G378R 
and I439S) were included. Of them, 14 were AMC, 7 were SMC and 4 CTR. Demographic 
and clinical data are shown in Table 1. We observed group differences in age (Kruskal-Wallis 
test p<0.05). CTR and AMC differed in EYO (Mann-Whitney U, p< 0.01), but not in age. In 
our sample, we observed a bias towards female participants due to the fact that women from 
our ADAD clinical cohort were more prone to participate in research studies than men. Seven 
AMC were classified as stage I - AMC, younger than 15 years from estimated onset (mean 
EYO=-18.8 years, SD: 3.16), and 7 AMC were classified as stage II - AMC, older than 15 
years from estimated onset (mean EYO=-7.95 years, SD: 7.14). 
 
3.2. Safety results.  






3.3. Visual assessment of PET images.  
Sixteen mutation carriers, all 7 SMC and 9 out of 14 AMC, showed abnormal (increased) 
FBB uptake at visual assessment at least in one of the areas studied. Seven of them (43.75%) 
showed both generalized uniform uptake and local striatal tracer uptake. They corresponded 
to 4 SMC and 3 AMC with EYO range -13 to 9.4 years and the following mutations: S169P, 
L173F, E120K, H163R, K239N, L173F. Two L282R AMC (12.5%) presented only 
generalized uniform cortical uptake. Two SMC (12.5%) with EYO 3.1 and 4 years and 
G209E and H163R mutations showed only striatal retention. Four AMC (25%) had focal 
cortical retention, with EYO range to -20.2 to -1.8 years and the K239N, L282R, G378R and 
V151M mutations. One SMC (6.25%) with EYO 7.3 and L286P mutation presented 
cerebellar tracer retention in addition to generalized uniform cortical uptake. This participant 
was the only SMC who did not show striatal uptake at visual inspection. The 9 participants 
with high striatal uptake were 6 SMC and 3 AMC. The 5 remaining AMC (EYO range: -24.4 
to -15.7) were negative in all the areas evaluated at visual inspection. Figure 1 provides one 
example of each of the amyloid patterns observed. All non-carriers were negative at visual 
inspection.   
 
3.4 Individual quantification 
We studied the individual FBB uptake quantifications in all the regions. The percentages of 
subjects with altered (above cutoff) values within each group and for each region are 
summarized in Figure 2. All SMC subjects showed regional SUVR values above the cutoff in 
all the areas studied except for caudate (85.7% positive subjects), putamen (85.7% positive), 
hippocampus (14.2% positive), amygdala (57.4% positive), enotorhinal cortex (0% positive), 
parahippocampal cortex (57.14% positive) and temporal pole (71.43% positive). 
Interestingly, the only SMC (EYO= 7.32 years, mutation L268P, and CDR=1) subject that did 
not show increased SUVR in caudate showed increased SUVR in the cerebellum. The 
youngest AMC who showed FBB above cutoff had an EYO of -20 years (7 out of 40 positive 
regions), and the 2nd youngest had an EYO of -16 years (20 out of 40 positive regions).  
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Of the stage I-AMC subjects, only the two subjects mentioned above, showed SUVR above 
cutoff in some areas: bankssts, precuneus, inferior and superior parietal, supramarginal and 
lateral occipital (Figure 2). However, all the stage II-AMC subjects presented at least one area 
with SURV above the cutoff. CTR subjects present normal SURV values in all the areas 
except for the pallidum.  
The results obtained using the original methods defined in Bullich et al. (2017) are included 
in Supplementary Material, together with the comparative analysis between both sets of 
results. In summary, we found a strong correlation between both sets of measures, and we 
obtained similar results both for group comparison analyses and in the rate of 
positive/negative subjects per region. We also tested the regional variability of the thresholds 
and we concluded that the number of subjects classified as positive or negative was almost 
identical when using regional vs global thresholds (See Supplementary Material for results 
and further discussion).  
  
3.5. Group differences in SUVR. 
In SMC, we found higher FBB uptake in all the regions, compared with CTR (all surviving 
FDR threshold: p= 0.023, Figure 3). In AMC, the caudate and all cortical areas, with the 
exception of the entorhinal cortex, showed increased SUVR compared with CTR (all 
surviving FDR threshold: p=0.019, Figure 3). When AMC subjects were divided according to 
EYO, we found increased uptake (p<0.05, uncorrected) in stage I-AMC compared to CTR in 
21 out of 40 regions including 20 cortical ROIS and the caudate. However, none of these 
differences survived FDR correction. In stage II-AMC, compared with CTR, we also found 
higher uptake in the hippocampus and in the rest of cortical areas (all surviving FDR 
threshold: p=0.037, Figure 4A and supplementary material).  
 
3.6. Correlation between SUVR and EYO.  
For all MC, we observed significant correlations between SUVR and EYO in all the areas 
studied (all surviving FDR threshold: p=0.0023, see values in supplementary material). In 
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AMC, we found correlations between SUVR and EYO in many cortical areas and in the 
amygdala (all surviving FDR threshold: p=0.035), which were not seen in SMC. The regions 
with the strongest significant correlations (r>0.62, p<0.05, FDR corrected) are shown in 
Figure 5. 
 
3.7. Cortical Thickness  
In AMC, we found higher CTh compared to CTR in bankssts, paracentral, parsopercularis, 
parstriangularis, rostral middle frontal, and superior temporal (p<0.05, Figure 4B). In SMC, 
we found thinner cortex compared to controls in precuneus and inferior parietal, superior 
parietal and supramarginal regions (all p<0.05, Figure 4B). We found negative correlation 
with EYO in MC in the bankssts, the fusiform, the inferior parietal, the middle temporal, the 
postcentral, the precuneus and the supramarginal. We observed that all the areas mentioned 
above, with significantly increased CTh in AMC or decreased CTh in SMC, showed also 
significant Aβ deposition compared with CTR (Figure 4).  
 
DISCUSSION 
We examined the spatial pattern of FBB retention in ADAD due to PSEN1 mutations. 
Consistent with the amyloid hypothesis and according with previous findings with other 
tracers and in other cohorts, we found increased FBB uptake in PSEN1 mutation carriers in 
cortical and subcortical areas, found in precuneus, bankssts, supramarginal, superior and 
inferior parietal and lateral occipital in asymptomatic subjects younger than two decades 
before the predicted symptoms onset, suggesting progressive deposition of fibrillar A . We 
identified areas with strong correlation between FBB uptake and EYO among which 
outstands the rostral anterior cingulate, suggesting that this area could be used to track the 
progressive fibrillar A  deposition across the disease. Striatal pathological uptake was 
observed in 50% of the positive scans and cerebellar uptake was only in one SMC at visual 
examination. In addition, we identified areas of increased CTh in AMC, in accordance with 
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previous studies (Fortea et al., 2010; Sala-Llonch et al., 2015), as the bankssts and the 
precuneus, which also presented significant amyloid deposition in early AMC stages. Besides 
not being a longitudinal study, our findings in subjects at different EYO suggest a progressive 
increase in amyloid deposition when approaching disease onset. In terms of safety, the use of 
FBB PET was shown to be safe and well-tolerated in this population. 
 
Overall, we demonstrate the capability of FBB-PET imaging to depict amyloid deposition 
changes up to 20 years before the clinical onset of AD. Notably, we described regional 
patterns similar than those reported in other cohorts with other tracers, besides potential 
differences in the degree of retention between amyloid binding detected with 18C-PIB and 
FBB (Villemagne et al., 2012). Studies on the DIAN cohort, both cross-sectionally (Bateman 
et al., 2012; Benzinger et al., 2013; Oxtoby et al., 2018), and longitudinally (Gordon et al., 
2018) reported amyloid deposition in nearly every cortical region 15 years before the 
estimated age of onset for ADAD mutation carriers, measured with PIB-PET. Also using PIB, 
another study reported higher striatum uptake in presymptomatic ADAD subjects 17 years 
before the estimated onset and longitudinal increases in frontal cortex and in putamen when 
subjects approached the age of onset (Rodriguez-Vieitez et al., 2016). In presymptomatic 
PSEN1 E280A mutation carriers, using 18F-florbetapir, it has been found that fibrillar A  
began to accumulate about 16 years before the predicted median age of mild cognitive 
impairment onset, in anterior and posterior cingulate, precuneus, and parietotemporal and 
frontal cortex, and in basal ganglia (Fleisher et al., 2015). In addition, studies in sporadic AD 
(Villemagne et al., 2013) have found amyloid PET changes up to 17 years before the stage of 
mild dementia, suggesting similarities between ADAD and late-onset sporadic AD in the 
chronology of the progressive amyloid deposition.  
 
As regards the regional specificity, using PIB, striatal amyloid accumulation was described as 
a specific feature of ADAD (Klunk et al., 2007). In our sample, using FBB, we find a regional 
pattern of alterations in ADAD, which was in general characterized by diffuse cortical uptake 
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accompanied by slight striatal alterations. Striatal uptake was frequent but not universal in our 
subjects. Interestingly, the only SMC who did not show altered FBB uptake in the striatum 
showed relevant cerebellar uptake. Increased FBB uptake in caudate appeared in the early 
presymptomatic phase, while hippocampal uptake increase appeared in the last years of the 
presymptomatic stage, it was significantly higher in stage II-AMC (less than 15 years before 
the predicted age of onset), with no differences in younger asymptomatic carriers, compared 
to non-carriers. Additionally, only one of the mutation carriers showed FBB uptake above the 
cut-off in the hippocampus. Our study did not show relevant amyloid tracer retention in 
ADAD in the hippocampus, similar to previous studies (Benzinger et al., 2013; Gordon et al., 
2018; Rodríguez-Vietez et al., 2016) and in agreement to classical neuropathological studies 
that revealed the hippocampus only presented mild deposits of amyloid (Braak and Braak, 
1991). The rest of subcortical structures studied showed abnormal deposition in SMC, but not 
in AMC.  
We found strong correlations between FBB uptake and EYO for all MC in all the regions 
studied. These were also observed in AMC, but not in SMC, suggesting that time does not 
relevantly affect amyloid accumulation after the symptoms onset. If we exclude the pallidum, 
which may present unspecific binging, considering that CTR also presented high uptake, the 
anterior rostral cingulate appeared as the region showing strongest correlations in AMC, and 
thus it can be considered as a candidate region to be used to track amyloid deposition (rho = 
0.75 in AMC and 0.83 in MC). In addition, the precuneus that has been proposed as a 
candidate region by other authors (Bateman et al., 2012; Benzinger et al., 2013; Gordon et al., 
2018), also showed strong correlations in our sample (rho = 0.62 in AMC and 0.77 in MC).  
In previous studies, we described increased CTh in AMC compared with controls, at a mean 
of 16 years from symptoms onset, in temporoparietal cortex, precentral and postcentral 
cortices, and pars triangularis and pars opercularis regions, accompanied by increased caudate 
volume (Fortea et al., 2010; Sala-Llonch et al., 2015). We then speculated that 
neuroinflammation and/or accumulation of amyloid species preceding neurodegeneration 
could account for this phenomenon. Here, we observed that those regions showed increased 
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FBB uptake very early on in the disease course, suggesting pathological fibrillar amyloid 
deposition in areas with increased thickness (Fortea et al., 2010; Sala-Llonch et al., 2015). In 
the same line, Rodriguez-Vieitez and collaborators (Rodriguez-Vieitez et al., 2016) described 
that initially high followed by declining astrocytosis in ADAD carriers, at the time of early 
amyloid deposition, suggesting astrocyte activation is implicated in the early stages of AD 
pathology (Quiroz et al., 2018).  
 
Notably, in this study, we used a semi-automated method that uses individual anatomical 
information, PET-MRI registration, and PVE correction (Greve et al., 2016). Even if we have 
proven that the classification into positive/negative scans is similar to that obtained by visual 
ratings, automatic quantifications allowed us providing an accurate description of regional 
alterations, discriminating areas affected differently at each stage of the disease progression.  
 
It is a matter of discussion whether different amyloid tracers bind to identical sites on A  
fibrils, offering the same ability to detect the regional A  burden or not. In this sense, one of 
the main contributions of our work is the confirmation that FBB is able to detect the amyloid 
plaques observed in PSEN1 carriers as soon as two decades before predicted age of onset. On 
the other hand, previous studies refer to the precuneus as the preferred area to study the 
progressive deposition of amyloid using amyloid PET. Here, besides validating the results on 
the precuneus, we discuss that other areas, as the anterior cingulate, are also good candidates 
to monitor amyloid uptake. 
 
Overall, even when most of our results are in line with previous studies with other tracers, 
suggesting that most of the effects described are related to real amyloid deposition and not to 
an unspecific tracer effect, we should acknowledge some limitations.  First, the sample size 
limits the strength of the results and precluded some of the potential analysis, but on the other 
hand, it is relevant considering that is a unicentric study and no other data are available with 
FBB in this population. The second limitation is that this is a cross-sectional study and even if 
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cross-sectional studies have provided evidences further proved in longitudinal studies, the 
magnitude of the effect or the temporal pattern of changes may differ with real longitudinal 
studies. Other limitation is the use of a FBB cut-off positivity that was obtained for sporadic 
AD. However, the results obtained are congruent with what could be expected according to 
the literature. Finally, our approach relied upon a familial age of symptom onset as a proxy 
for disease progression, which limits the accuracy of predictions due to the potential 
imprecision in such estimates (Ryman et al., 2014). Giving that it is currently not possible to 
predict the exact age of onset for each AMC subject using individual biomarkers, in the future 




In summary, we confirm and expand previous findings of very early, progressive and region 
dependent amyloid tracer uptake in ADAD in an independent unicentric cohort (Barcelona 
cohort), with a different amyloid tracer, FBB. Our findings would suggest that FBB disclose a 
similar spatial pattern and chronology of tracer uptake to that described in previous 
publications with other amyloid tracers in ADAD.  
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TABLES :  
 
 CTR AMC SMC P 
N= 25  4 14 7  
Age, y, mean (SD) 48.37 (10.01) 37.11 (8.79) 51.88 (2.32) p= 0.005 
Sex, M/F 1/3 1/13 5/2 p= 0.01 
EYO, y, mean (SD) 2.06 (4.56) -13.38 (7.73)* 4.88 (2.58) p< 0.001 
MMSE, mean (SD) 30 28.86 (1.56) 22.43 (3.31) p< 0.001 
CDR total, mean (SD) 0 0 1.07 (0.67) p< 0.001 
CDR-SOB, mean (SD) 0 0 4.57 (3.62) p< 0.001 
 
Table 1. Participant demographics and clinical variables. 
CTR: non-carriers; AMC: asymptomatic mutation carriers; SMC: symptomatic mutation 
carriers; SD: standard deviation, P values obtained by Kruskal-Wallis test. * indicates that 













Figure 1. Visual patterns of FBB uptake observed in the PSEN1 mutation carriers. A). 
Negative scan. B). Generalized uniform uptake C). Focal occipital uptake. D). Striatal and 
focal cortical uptake. E). Cerebellar uptake.  
 
 Figure 2. Percentage of subjects with increase individual SUVR values (cutoff = 0.78) for 
each region at each stage. On the right, representation of the percentages on a standard 
surface brain.  
 
Figure 3. Mean SUVR within each ROI for controls (CTR), asymptomatic mutation carriers 
(AMC) and symptomatic mutation carriers (SMC). Only areas with significant differences 
between CTR and AMC are shown in the figure. Differences between CTR and SMC are 
significant for all regions studied. 
 
Figure 4. Summary of FBB and CTh group comparisons. In (A), areas with significant FBB 
uptake differences in the comparison with the CTR group (p<0.05 in the Kruskal-Wallis test), 
as indicated with gray boxes (light gray for stage I AMC, medium gray for stage II AMC and 
dark gray for SMC). The brain representation shows significant cortical parcellations on a 
standard surface brain. Green-yellow scale indicates the degree of differences in SUVR for 
each region of each group compared to CTR.  In (B), areas with significant CTh differences 
in the comparison with the CTR group (p<0.05 in the Kruskal-Wallis test), as indicated with 
blue boxes (decreased CTh) and red boxes (increased CTh). The brain representation shows 
significant cortical parcellations on a standard surface brain. Blue-Red colors indicate the 
direction of differences for each region of each group compared to CTR, following the same 
legend as the box grid. See main text for differences surviving multiple comparisons.  
 
Figure 5. Correlation between SUVR and EYO for each group. For each region, the result of 
the Spearman correlation within the AMC group is shown on the bottom-right corner. Only 
regions with correlation of r>0.62 are shown and corrected p<0.05.  The detailed results of the 
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- FBB-PET is safe in ADAD and useful to track amyloid progression. 
- PSEN1 carriers showed progressive amyloid uptake. 
- Amyloid uptake starts 15 years before onset in cortical areas and in the caudate. 
- The rostral anterior cingulate can track disease progression in ADAD. 
- Amyloid uptake coincides with increased cortical thickness. 
 
*Highlights (for review)
